Market Place
Sourcing Support
Expanded HyBryte Shows Positive Results In Early-Stage Lymphoma
09 Jul 2024 //
PR NEWSWIRE
Soligenix stock sinks as FDA refuses lymphoma application
15 Feb 2023 //
FIERCE BIOTECH
Soligenix opens patient enrolment for Phase IIa trial of psoriasis therapy
19 Dec 2022 //
CLINICALTRIALSARENA
Soligenix opens patient enrolment for Phase IIa trial of psoriasis therapy
19 Dec 2022 //
CLINICALTRIALSARENA
FDA Clears Soligenix`s IND for PII Trial of Synthetic Hypericin in Psoriasis
28 Jun 2022 //
PRNEWSWIRE
Soligenix to Advance Synthetic Hypericin Development in Psoriasis
16 Sep 2021 //
BIOSCAPE
Soligenix Announces Recent Accomplishments And First Quarter 2020
15 May 2020 //
PRNEWSWIRE
Soligenix gets European patent for therapeutic use of synthetic hypericin
08 Apr 2020 //
PHARMABIZ
Soligenix`s stock climbs as phase 3 lymphoma trial hits goal
19 Mar 2020 //
PRNEWSWIRE
Soligenix gets US patent for improved prod. of synthetic hypericin composition
25 Oct 2019 //
PHARMABIZ
Soligenix Receives US Patent for Improved Production of Synthetic Hypericin
25 Oct 2019 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.